Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Editas Medicine is a biotechnology business based in the US. Editas Medicine shares (EDIT) are listed on the NASDAQ and all prices are listed in US Dollars. Editas Medicine employs 226 staff and has a trailing 12-month revenue of around $19.7 million.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $8.37 |
|---|---|
| 52-week range | $7.48 - $21.60 |
| 50-day moving average | $9.19 |
| 200-day moving average | $12.08 |
| Wall St. target price | $13.06 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-3.23 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $8.37 from 2023-03-17
| 1 week (2023-03-13) | -0.71% |
|---|---|
| 1 month (2023-02-17) | -17.54% |
| 3 months (2022-12-20) | -8.62% |
| 6 months (2022-09-20) | -42.71% |
| 1 year (2022-03-18) | -54.41% |
|---|---|
| 2 years (2021-03-19) | -81.40% |
| 3 years (2020-03-20) | 19.08 |
| 5 years (2018-03-20) | 38.14 |
| Revenue TTM | $19.7 million |
|---|---|
| Gross profit TTM | $-155,246,000 |
| Return on assets TTM | -23.7% |
| Return on equity TTM | -48.22% |
| Profit margin | 0% |
| Book value | $5.36 |
| Market capitalisation | $573.1 million |
TTM: trailing 12 months
We're not expecting Editas Medicine to pay a dividend over the next 12 months.
Over the last 12 months, Editas Medicine's shares have ranged in value from as little as $7.48 up to $21.595. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Editas Medicine's is 1.8979. This would suggest that Editas Medicine's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Editas Medicine, Inc. , a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc.
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
Steps to investing in the Vanguard (VTI) Total Stock Market ETF.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.